NR 566 Advanced Pharmacology Care of the Family Midterm Review - Chamberlain College
Latest 2023 / 2024
- How to measure therapeutic effect of HIV therapy
- RNA LEVELS
- baseline
- 2-4 weeks, no later than 8 weeks
- every 4-8 weeks until suppressed
- after suppressed every 3-4 months
- Long-term virologic suppression x2 years
- every 6 months
- any change in status = chemo/steroids
- every 3 months
- Protease Inhibitor (PIs) Lopinavir - high risk patients
- ORAL solution: Contraindicated for full-term infants (until 14 days after
birth) and premature (until 14 days after due date)
- cardiac disease
- Hx prolong QT
- Protease Inhibitor (PIs) Lopinavir - Lifespan considerations
- Children: Safe after 14 days old 1 / 3
- Pregnancy: approved w/ higher risks
- Protease Inhibitor (PIs) Lopinavir/ritonavir - adverse effects
- - QT prolongation
- Protease Inhibitor (PIs) Saquinavir - Lifespan considerations
- Children
- Not identified as safe/efficient in children younger than 16
- Pregnancy
- Safest PI for pregnancy
- HIV treatment is recommended in pregnancy
- Protease Inhibitor (PIs) Saquinavir - adverse reactions
- - QT prolongation
- Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Didanosine (ddI) - high
risk patient
- Increase risk of pancreatitis with alcohol use, pancreatitis, and IV pentamide
- Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Didanosine (ddI) -
Lifespan considerations
- Children
- approved in 6 years + weighing 20kg
- Pregnancy 2 / 3
- Less risk
- Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Zidovudine - Lifespan
consideration
- Children
- neonates
- Pregnancy
- increased risk
- Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs): Zidovudine - high risk
patients
- Hx of
- granulocytosis
- low H&H
- low vit B12
- low folic acid
- current use of meds that cause myelosuppe
- How to measure therapeutic effect of HIV therapy
- CD4 counts
- w/ suppressed RNA levels = increase CD4 levels
- Check levels
- baseline
- at 3 month mark
- during 1st 2 years every 3-6 months during therapy
- long-term suppression
- / 3